Back to Directory Scott Watson Email scottwatson@westat.com Phone (415) 494-5575 Institution Westat Inc. Title Address Westat Inc. 1441 W. Montgomery Ave. Rockville, MD 20850 United States of America Request an Update Affiliated Studies IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed P1052: Abacavir PK Study in HIV-1 Infected Adolescents and Young Adults DAIDS Number 10194 Research Area Other Study Status Concluded P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling P1059: Phase I Trial of Recombinant Vaccines in HIV+ Young Adults DAIDS Number 10051 Research Area Other Study Status Concluded IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30072 Research Area Complications & Comorbidities Study Status Concluded Show All
IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
P1052: Abacavir PK Study in HIV-1 Infected Adolescents and Young Adults DAIDS Number 10194 Research Area Other Study Status Concluded
P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling
P1059: Phase I Trial of Recombinant Vaccines in HIV+ Young Adults DAIDS Number 10051 Research Area Other Study Status Concluded
IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30072 Research Area Complications & Comorbidities Study Status Concluded